90-90-90 HIV Goals Top-of-Mind at Geneva Summit

The 90-90-90 targets for HIV will dominate discussion at the upcoming Controlling the HIV Epidemic with Antiretrovirals Summit 2016 in Geneva.

“When we launched this series of summits several years ago, we did not have consensus on the importance of scaling up treatment as prevention and pre-exposure prophylaxis,” said JosÂŽ Zuniga, PhD, president of the International Association of Providers of AIDS Care.

“We spent a lot of time building that consensus and moving stakeholders to support this intervention, which ultimately is the foundation for obtaining the 90-90-90 targets,” he told Medscape Medical News.

The targets set by the United Nations (UN) General Assembly are designed to end the AIDS epidemic by 2030. The initiative sets out three targets; by 2020, 90% of people with HIV infection will be diagnosed, 90% of people diagnosed will be on antiretroviral therapy, and the virus will be suppressed in 90% of people receiving antiretroviral therapy.

In his keynote address, Michel SidibÂŽ, executive director of UN AIDS, will discuss the strategies, emerging opportunities, and political processes involved in meeting the 90-90-90 targets. Antiretroviral suppression and pre-exposure prophylaxis (PrEP) will play a major role in the achievement of these goals.

“One of the big topics we are going to address is where we stand with PrEP,” said Dr Zuniga. “PrEP used to prevent the transmission of HIV, often taken by partners of people living with HIV, hasn’t been approved in many countries, and uptake is slow in countries where it has been approved, including the United States.”

However, in the United Kingdom, the National Health Services has gone to court to try to force the government to pay for PrEP, he reported.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below